Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

This study is testing a drug called chidamide (a type of targeted therapy) combined with a standard chemotherapy regimen (CHOP) for people newly diagnosed with a specific type of T-cell lymphoma called peripheral T-cell lymphoma with a follicular helper T-cell pattern. The goal is to see if adding chidamide improves outcomes. **You may be eligible if...** - You are between 18 and 75 years old - You have been newly diagnosed with angioimmunoblastic T-cell lymphoma (AITL), follicular T-cell lymphoma, or related subtypes confirmed by biopsy - You have not yet received any treatment for lymphoma - You have measurable disease on imaging - Your overall health is good enough for chemotherapy **You may NOT be eligible if...** - You have received prior chemotherapy, radiation, or immunotherapy for lymphoma - You are eligible for and willing to undergo stem cell transplant (unless you refuse) - Your organ function does not meet the study requirements Talk to your doctor to see if this trial is right for you.